PL346155A1 - 1h-imidazopyridine derivatives - Google Patents

1h-imidazopyridine derivatives

Info

Publication number
PL346155A1
PL346155A1 PL99346155A PL34615599A PL346155A1 PL 346155 A1 PL346155 A1 PL 346155A1 PL 99346155 A PL99346155 A PL 99346155A PL 34615599 A PL34615599 A PL 34615599A PL 346155 A1 PL346155 A1 PL 346155A1
Authority
PL
Poland
Prior art keywords
imidazopyridine derivatives
imidazopyridine
derivatives
Prior art date
Application number
PL99346155A
Inventor
Hideo Kato
Jun Sakaguchi
Makoto Aoyama
Tomoyuki Izumi
Ken-Ichi Kato
Original Assignee
Hokuriku Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokuriku Seiyaku Co filed Critical Hokuriku Seiyaku Co
Publication of PL346155A1 publication Critical patent/PL346155A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL99346155A 1998-08-12 1999-08-12 1h-imidazopyridine derivatives PL346155A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24106298 1998-08-12
JP11216125A JP2000119271A (en) 1998-08-12 1999-07-30 1h-imidazopyridine derivative
PCT/JP1999/004381 WO2000009506A1 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives

Publications (1)

Publication Number Publication Date
PL346155A1 true PL346155A1 (en) 2002-01-28

Family

ID=26521247

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99346155A PL346155A1 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives

Country Status (21)

Country Link
US (1) US6518265B1 (en)
EP (1) EP1104764A4 (en)
JP (1) JP2000119271A (en)
CN (1) CN1323307A (en)
AU (1) AU744388B2 (en)
BG (1) BG105271A (en)
BR (1) BR9914306A (en)
CA (1) CA2339562A1 (en)
CZ (1) CZ292544B6 (en)
EA (1) EA200100230A1 (en)
HK (1) HK1042295A1 (en)
HR (1) HRP20010144A2 (en)
HU (1) HUP0103406A3 (en)
IL (1) IL141226A0 (en)
NO (1) NO20010676L (en)
NZ (1) NZ509939A (en)
PL (1) PL346155A1 (en)
SK (1) SK1942001A3 (en)
TR (1) TR200100439T2 (en)
TW (1) TW533209B (en)
WO (1) WO2000009506A1 (en)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CZ20012446A3 (en) 1999-01-08 2002-01-16 3M Innovative Properties Company Pharmaceutical preparation intended for treating mucous membrane disease
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
HUP0204474A3 (en) * 2000-02-09 2004-07-28 Hokuriku Pharmaceutical 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
WO2002016370A1 (en) * 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
DE60119939T2 (en) * 2000-09-21 2006-11-30 Smithkline Beecham P.L.C., Brentford CHINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
AU2006216669A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
JP4447914B2 (en) 2001-11-29 2010-04-07 スリーエム イノベイティブ プロパティズ カンパニー Drugs containing immune response modifiers
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1478327B1 (en) * 2002-02-22 2015-04-29 Meda AB Method of reducing and treating uvb-induced immunosuppression
AU2003222106A1 (en) * 2002-04-03 2003-10-20 Bristol-Myers Squibb Company Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
CA2488801A1 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
ATE488246T1 (en) 2002-08-15 2010-12-15 3M Innovative Properties Co IMMUNO-STIMULATORY COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
EP1542688A4 (en) * 2002-09-26 2010-06-02 3M Innovative Properties Co 1h-imidazo dimers
WO2004035579A1 (en) * 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited Imidazopyridine derivative, process for producing the same, and use
ES2372600T3 (en) * 2002-11-06 2012-01-24 Aska Pharmaceutical Co., Ltd. DERIVED FROM PIRAZOLONAFTIRIDINA.
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
JP2006512391A (en) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー Combination immunostimulant
EP1592302A4 (en) * 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8
JP2006519020A (en) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Selective regulation of TLR-mediated biological activity
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
MXPA05009488A (en) * 2003-03-07 2005-12-14 3M Innovative Properties Co 1-amino 1h-imidazoquinolines.
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
CA2518082C (en) * 2003-03-13 2013-02-12 3M Innovative Properties Company Methods for diagnosing skin lesions
JP4891066B2 (en) 2003-03-13 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー How to improve skin quality
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2521682A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co Compositions and methods for induction of opioid receptors
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
CA2534042A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Compositions for encapsulation and controlled release
CA2534313C (en) * 2003-08-05 2013-03-19 3M Innovative Properties Company Formulations containing an immune response modifier
JP2007502293A (en) 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Hydroxylamine-substituted imidazo-containing compounds
US7678909B1 (en) * 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004266657B2 (en) 2003-08-14 2009-07-02 3M Innovative Properties Company Lipid-modified immune response modifiers
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
EP1658076B1 (en) * 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
CN1845736A (en) * 2003-09-02 2006-10-11 3M创新有限公司 Methods related to the treatment of mucosal associated conditions
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
WO2005079195A2 (en) 2003-10-03 2005-09-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
AR046046A1 (en) 2003-10-03 2005-11-23 3M Innovative Properties Co IMIDAZOQUINOLINAS ALCOXI SUBSTITUTED. PHARMACEUTICAL COMPOSITIONS.
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005041891A2 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
RU2006121646A (en) * 2003-11-21 2008-01-10 Новартис АГ (CH) 1H-IMIDAZOCHINOLINE DERIVATIVES AS PROTEINKINASE INHIBITORS
EP1686992A4 (en) 2003-11-25 2009-11-04 3M Innovative Properties Co Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
BRPI0416936A (en) 2003-11-25 2007-01-16 3M Innovative Properties Co substituted imidazo ring systems and methods
EP1689361A4 (en) * 2003-12-02 2009-06-17 3M Innovative Properties Co Therapeutic combinations and methods including irm compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005076783A2 (en) 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
EP1701955A1 (en) * 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US7888349B2 (en) 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co Enhancement of immune responses
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
WO2005089317A2 (en) 2004-03-15 2005-09-29 3M Innovative Properties Company Immune response modifier formulations and methods
WO2005087775A1 (en) * 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. Tricyclic heterocyclic compound and medicinal composition containing the compound as active ingredient
AU2005228150A1 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co Methods, compositions, and preparations for delivery of immune response modifiers
WO2006126981A2 (en) * 2004-04-28 2006-11-30 3M Innovative Properties Company Compositions and methods for mucosal vaccination
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
DK1765310T3 (en) 2004-05-28 2016-01-11 Oryxe MIXING for transdermal delivery of LAV AND HØJMOLEKYLVÆGTFORBINDELSER
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7884207B2 (en) 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006026470A2 (en) * 2004-08-27 2006-03-09 3M Innovative Properties Company Hiv immunostimulatory compositions
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
AU2005282726B2 (en) 2004-09-02 2011-06-02 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co Adjuvant for dna vaccines
EP1831214A1 (en) * 2004-12-27 2007-09-12 Usv Limited A process for preparation of 4-amino-1-isobutyl-1h-imidazo[4,5-c]-quinoline (imiquimod)
JP5543068B2 (en) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー Chiral fused [1,2] imidazo [4,5-c] cyclic compound
PT1830876E (en) * 2004-12-30 2015-07-13 Meda Ab Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006073939A2 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7683171B2 (en) 2005-02-04 2010-03-23 Bristol-Myers Squibb Company 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
US8378102B2 (en) 2005-02-09 2013-02-19 3M Innovative Properties Company Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
WO2006091567A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1850849A2 (en) * 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
JP2008531568A (en) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド Imidazonaphthyridine substituted with hydroxyalkyl
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
WO2006099275A2 (en) 2005-03-14 2006-09-21 3M Innovative Properties Company Method of treating actinic keratosis
CA2602590A1 (en) * 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
EP1874345B1 (en) * 2005-04-25 2012-08-15 3M Innovative Properties Company Immunostimulatory compositions
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2008545008A (en) * 2005-06-30 2008-12-11 プロシディオン・リミテッド GPCR agonist
AU2006287270A1 (en) * 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
KR20080083270A (en) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
US20080269131A1 (en) * 2005-11-10 2008-10-30 Smithkline Beecham Corporation Inhibitors of Akt Activity
WO2007058852A2 (en) * 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibitors of akt activity
PT3184526T (en) 2005-12-13 2018-12-19 Incyte Holdings Corp Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor
CA2640672A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
WO2007100634A2 (en) * 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
CA2669199C (en) 2006-11-20 2015-12-29 Novartis Ag Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US20080312259A1 (en) 2007-06-13 2008-12-18 Incyte Corporation SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
WO2009125808A1 (en) * 2008-04-11 2009-10-15 第一三共株式会社 Aminocyclohexyl derivative
WO2009125809A1 (en) * 2008-04-11 2009-10-15 第一三共株式会社 Piperidine derivatives
CN106967070A (en) 2009-05-22 2017-07-21 因塞特控股公司 It is used as the compound of JAK inhibitor
ES2487542T3 (en) 2009-05-22 2014-08-21 Incyte Corporation N- (hetero) aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo [2,3-d] pyrimidines and pyrrol-3-yl-pyrrolo [2,3-d] pyrimidines as Janus kinase inhibitors
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
TWI766281B (en) 2010-03-10 2022-06-01 美商英塞特控股公司 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (en) 2010-05-21 2013-02-27 Incyte Corp TOPICAL FORMULATION FOR A JAK INHIBITOR
ES2943385T3 (en) 2010-08-17 2023-06-12 3M Innovative Properties Company Modifying compound of the lipidated immune response and its medical use
AR083933A1 (en) 2010-11-19 2013-04-10 Incyte Corp PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS
EP2648733A1 (en) * 2010-12-06 2013-10-16 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
MX355623B (en) 2011-06-03 2018-04-25 3M Innovative Properties Co Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom.
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EA201490042A1 (en) 2011-06-20 2014-10-30 Инсайт Корпорейшн AZETIDINYL-PHENYL-, PYRIDYL- OR PYRAZYNYLKARBOXAMID DERIVATIVES AS INHIBITORS
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
TR201814710T4 (en) * 2011-09-30 2019-01-21 C&C Res Lab Newly Developed Alternating Ring Heterocyclic Derivatives and Their Usage
WO2013052550A2 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
US10076535B2 (en) 2012-04-27 2018-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
CN107936039A (en) 2012-11-01 2018-04-20 因赛特公司 Tricyclic condensed thiophene derivant as JAK inhibitor
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
PT2941233T (en) 2013-01-07 2020-11-13 Univ Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
HUE057262T2 (en) 2013-03-06 2022-04-28 Incyte Holdings Corp Processes and intermediates for making a jak inhibitor
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
MA39987A (en) 2014-04-30 2017-03-08 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
WO2015171526A2 (en) * 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Tricyclic pyrazolopyridine compounds
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
WO2017044803A1 (en) 2015-09-09 2017-03-16 The United States Of America, As Represented By The Secretary Department Of Health And Human Service Expression vector delivery system and use thereof for inducing an immune response
EP3349717A4 (en) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. Approaches for improving skin hydration or moisturization
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
WO2017147597A1 (en) 2016-02-27 2017-08-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide vaccines comprising self-assembling polymer nanoparticles
RS62695B1 (en) 2016-10-03 2022-01-31 Highlightll Pharmaceutical Hainan Co Ltd Novel jak1 selective inhibitors and uses thereof
KR102009756B1 (en) * 2017-01-06 2019-08-12 고려대학교 세종산학협력단 Novel quinolinone derivatives and pharmaceutical composition for prevention or treatment of allergic diseases including asthma or atopic dermatitis comprising the same
WO2018128407A1 (en) * 2017-01-06 2018-07-12 고려대학교 세종산학협력단 Novel quinolinone derivative and pharmaceutical composition for preventing or treating allergic disease such as asthma or atopy comprising same as active ingredient
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN112105608B (en) 2018-01-30 2023-07-14 因赛特公司 Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
AU2019245420A1 (en) 2018-03-30 2020-11-12 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
WO2019226828A2 (en) 2018-05-22 2019-11-28 Avidea Technologies, Inc. Improved methods of manufacturing peptide-based vaccines
AU2019274654B2 (en) 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
KR20230146098A (en) 2018-05-23 2023-10-18 화이자 인코포레이티드 Antibodies specific for gucy2c and uses thereof
US20210353740A1 (en) 2018-09-23 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
WO2020072681A1 (en) 2018-10-03 2020-04-09 Avidea Technologies, Inc. Aromatic ring substituted amphiphilic polymers as drug delivery systems
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US20230026627A1 (en) 2019-04-17 2023-01-26 Vaccitech North America, Inc. Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery
MX2022006578A (en) 2019-12-17 2022-07-04 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN116323668A (en) 2020-07-17 2023-06-23 辉瑞公司 Therapeutic antibodies and uses thereof
US20230381112A1 (en) 2020-09-22 2023-11-30 Vaccitech North America, Inc. Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ
AU2021364709A1 (en) 2020-10-19 2023-06-01 Barinthus Biotherapeutics North America, Inc. Star polymer drug conjugates
EP4263553A1 (en) * 2020-12-17 2023-10-25 Zymeworks BC Inc. Imidazothienopyridine compounds and methods of use
EP4294431A1 (en) 2021-02-16 2023-12-27 Vaccitech North America, Inc. Self-assembling nanoparticles based on amphiphilic peptides
WO2024092030A1 (en) 2022-10-25 2024-05-02 Vaccitech North America, Inc. Self-assembling nanoparticles
WO2024092028A2 (en) 2022-10-25 2024-05-02 Vaccitech North America, Inc. Combination treatment regimes for treating cancer
WO2024100093A1 (en) 2022-11-09 2024-05-16 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US346905A (en) * 1886-08-10 Heney gulick
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DE3679780D1 (en) 1985-11-06 1991-07-18 Merck & Co Inc SUBSTITUTED AMINOSULFONYL-6-NITROBENZOIC ACID ESTERS OR AMIDES, METHOD FOR THE PRODUCTION AND MEDICINES THEREOF.
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ES2094772T3 (en) * 1990-06-01 1997-02-01 Kyowa Hakko Kogyo Kk DERIVATIVES OF IMIDAZONAFTIRIDINAS.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP3206078B2 (en) 1992-01-28 2001-09-04 株式会社ノーリツ Combustor model selection device
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
EP0894797A4 (en) * 1997-01-09 2001-08-16 Terumo Corp Novel amide derivatives and intermediates for the synthesis thereof

Also Published As

Publication number Publication date
BG105271A (en) 2001-11-30
CZ292544B6 (en) 2003-10-15
HUP0103406A3 (en) 2002-11-28
NO20010676D0 (en) 2001-02-09
CN1323307A (en) 2001-11-21
TR200100439T2 (en) 2001-05-21
SK1942001A3 (en) 2001-12-03
CA2339562A1 (en) 2000-02-24
AU744388B2 (en) 2002-02-21
JP2000119271A (en) 2000-04-25
HUP0103406A2 (en) 2002-02-28
NZ509939A (en) 2002-08-28
CZ2001503A3 (en) 2001-11-14
BR9914306A (en) 2002-05-21
WO2000009506A1 (en) 2000-02-24
NO20010676L (en) 2001-04-10
AU5197499A (en) 2000-03-06
US6518265B1 (en) 2003-02-11
TW533209B (en) 2003-05-21
IL141226A0 (en) 2002-03-10
HK1042295A1 (en) 2002-08-09
HRP20010144A2 (en) 2002-04-30
EP1104764A4 (en) 2003-01-15
EP1104764A1 (en) 2001-06-06
EA200100230A1 (en) 2001-10-22

Similar Documents

Publication Publication Date Title
IL141226A0 (en) 1h-imidazopyridine derivatives
PL345540A1 (en) Thiobenzimidazole derivatives
HU9900120D0 (en) Benzosulfone derivatives
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
HUP0003642A3 (en) N-alkanoylphenylalanine derivatives
GB9702194D0 (en) Sulphonide derivatives
ZA987602B (en) N-alkanoylphenylalanine derivatives
GB9809664D0 (en) a-Ketoamide derivatives
HU9801168D0 (en) Triazinylaminostilbene derivatives
EG23802A (en) 2-Phenylpyran-4-one derivatives
IL132982A0 (en) Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives
GB9715821D0 (en) Amidino-camptothecin derivatives
GB2321457B (en) 5-Aroylnaphthalene derivatives
GB9827729D0 (en) Thieno-indole derivatives
GB9701628D0 (en) Imino-aza-anthracyclinone derivatives
GB9725541D0 (en) Amino-benzothiazole derivatives
EP1061912A4 (en) Phenanthrofuran derivatives
ZA983116B (en) Arylsecocholadiene derivatives
IL139276A0 (en) Cyclohexenondioxthio chromanoyl derivatives
HK1042478A1 (en) 2-oxo-2h-quinoline derivatives
IL131159A0 (en) 4-Aminoethoxyindazole derivatives
GB9816279D0 (en) Arylthiazolidinedione derivatives
SI1051395T1 (en) N-hydroxyformamide derivatives
GB9706753D0 (en) Aralkoxy-morphinan derivatives
SI1005445T1 (en) N-alkanoylphenylalanine derivatives

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)